A. Lucarelli

Phase I and pharmacokinetic study of VEGF Trap administered subcutaneously (sc) to patients (pts) with advanced solid malignancies.

L. Schwartz, J. Cedarbaum, J. Koutcher, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacokinetic study of VEGF Trap administered subcutaneously (sc) to patients (pts) with advanced solid malignancies

L. Schwartz, J. Cedarbaum, J. Koutcher, 2004 .

A phase I trial of E7974 administered on days 1 and 15 of a 28-day cycle in patients with solid malignancies

N. Vogelzang, E. Schuck, S. Madajewicz, 2007 .

A phase 1 trial of E7974 administered on day 1 of a 21‐day cycle in patients with advanced solid tumors

A. Tan, L. Raez, E. Rubin, 2012, Cancer.

Brightline-1: phase II/III trial of the MDM2-p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS.

R. Maki, P. Schöffski, M. Lahmar, 2023, Future oncology.

A phase 1 trial of E7974 administered on day 1 of a 21‐day cycle in patients with advanced solid tumors

A. Tan, L. Raez, E. Rubin, 2012, Cancer.